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The effects of 6-(1O-hydroxydecyl)-2,3-dimethoxy-5-methyl-l,4_benzoquinone (CV-2619) on the respiration 
and non-respiratory oxygen consumption induced by ascorbate and Fe 2+ in rat brain mitochondria were 
studied. When CV-2619 (100 and 300 mg/kg) was orally administered to rats for 3 days, it increased the 
state 3 respiration stimulated by ADP, slightly decreased the state 4 respiration after the consumption of 
ADP and resulted in a significant increase of the respiratory control index (RCI) by 1419% for glutamate 
oxidation (p <O.Ol) and 10-17x for succinate oxidation (p <0.05), respectively. The RCI increasing effect 
of CV-2619 was dose dependent, but the compound had no effect on the ADP/O ratio. CV-2619 significant- 
ly suppressed by about 10% the non-respiratory oxygen consumption (p<O.O2), which closely associated 
with non-enzymatic reactions such as lipid peroxidation, membrane lysis and swelling of mitochondria. 
Thus, CV-2619 may contribute to stimulate the net ATP formation by the well-coupling of electron and 
energy transfer, and by the reduction of non-respiratory oxygen consumption in cerebral metabolism. 
Idebenone(CV-2619) Brain mitochondria State 3 respiration Respiratory control index 
Non-respiratory oxygen consumption Cerebral metabolism 
1. INTRODUCTION 2. MATERIALS AND METHODS 
CV-2619 is a novel compound that has protec- 
tive and ameliorating effects on biochemical and 
neurological changes due to cerebral vascular le- 
sions especially with ischemia or hypoxia [l-3]. It 
has also been reported that CV-2619 suppressed 
the reduction of ATP level in the rat ischemic brain 
t31. 
2.1. Materials 
From these findings, it is suggested that 
CV-2619 may influence or protect the respiration 
and energy metabolism in brain mitochondria. 
Here, we have studied the effects on the 
respiratory and phosphorylating activities of brain 
mitochondria from rats treated with CV-2619. We 
have also examined the non-respiratory oxygen 
consumption induced by ascorbate and Fe’+, 
which is closely associated with non-enzymatic 
reactions such as lipid peroxidation, membrane 
lysis and swelling of mitochondria [6-S]. 
6-(lo-Hydroxydecyl)-2,3-dimethoxy-5-methyl- 
1 ,Cbenzoquinone (idebenone, CV-2619) was syn- 
thesized in the Chemistry Laboratories of this Cen- 
tral Research Division [ 121. Calcium hopantenate 
(hopate, Tanabe Seiyaku Co.) and rotenone (Pro- 
fessor H. Fukami, Kyoto University) were kindly 
provided. Antimycin A was purchased from ICN 
Pharmaceutical Inc. Other chemicals were ob- 
tained from commercial products of highest 
available purity. Male Wistar rats (9-l 1 weeks old) 
were used. They had free access to water and a 
laboratory chow, CE-2 (CLEA, Japan) until 
death. CV-2619 (100 and 300 mg/kg) and calcium 
hopantenate (500 mg/kg) suspended with gum 
arabic solution (5%) were orally administered to 
rats (n = 3-5) for 3 days (at 9 a.m.). 
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2.2. Isolation of mitochondria 
Brain mitochondria were isolated according to 
the method of Ozawa et al. [4] from the pooled 
brains of rats 1 h after the final administration of 
drugs. The isolation procedures are briefly de- 
scribed below. Following decapitation of the rats 
by a guillotine, the brain was removed and put into 
an ice-cold medium containing 0.3 M mannitol 
and 0.1 mM EDTA (pH 7.4) precisely 20 s after 
the decapitation. After the cerebellum and brain 
stem were removed, the pooled cerebral hemi- 
spheres from rats were washed and homogenized 
in the medium with a loosely fitted teflon homoge- 
nizer. The homogenate was centrifuged at 600 x g 
for 8 min and the supernatant was subjected to 
further centrifugation at 10000 x g for 10 min. 
The resultant pellet was washed once with the 
medium by centrifugation as above and finally 
suspended with 1 ml of the medium. Isolated 
mitochondria were kept on ice and used within 4 h. 
Mitochondrial protein was determined by the 
method of Lowry et al. [5] with bovine serum 
albumin as a standard. 
2.3. Measurement of oxygen consumption 
The mitochondrial respiration was measured by 
the oxygen electrode operated at room temperature 
(23-24°C) using an Oxygraph Model S/6 (Gilson 
Medical Electronics) in a reaction mixture contain- 
ing 0.3 M mannitol, 10 mM KCl, 5 mM potassium 
phosphate, 0.2 mM EDTA, 10 mM Tris-HCl (pH 
7.4), 1.14-1.47 mg mitochondrial protein and 
8 mM glutamate, in a final volume of 1.7 ml. In 
succinate oxidation, 8 mM succinate and 4 pg 
rotenone were substituted for glutamate, and 
0.57-0.74 mg protein of mitochondria were used. 
State 3 respiration was initiated by the addition of 
250pM ADP with glutamate as substrate or 
147 /cM ADP with succinate as substrate. State 4 
respiration was the rate of oxygen consumption 
after the consumption of ADP. The respiratory 
control index (RCI) was expressed as the ratio of 
the rate of oxygen consumption in state 3 and state 
4. ADP/O ratio was calculated as the ratio of add- 
ed amount of ADP to the total oxygen consump- 
tion during state 3 respiration. 
The rate of non-respiratory oxygen consumption 
induced by ascorbate and Fe2+ was also measured 
in the same reaction mixture as described above 
without substrate and ADP. After the addition of 
mitochondria (O&~-0.74 mg protein) and FeS04 
(29 FM), the reaction was followed by the addition 
of ascorbate (590 PM) for the measurement of ox- 
ygen consumption. 
2.4. Statistical analysis 
Data are represented as mean + SD and 
statistical analyses were performed by the Stu- 
dent’s t-test. 
3. RESULTS 
CV-2619 (100 and 300 mg/kg) and calcium 
hopantenate (500 mg/kg) for reference was orally 
Glutamate 
CV-2619 
(300 Wkg/doy) 
Succlnate 
\ 
CV-2619 
(300 mg/kWdaV) 
I min 
Fig. 1. Oxygen electrode recording of brain mitochondria 
respiring in the presence of glutamate or succinate as 
substrate. CV-2619 (300 mg/kg) was orally administered 
to rats for 3 days. Brain mitochondria were isolated and 
respiration was measured in a reaction mixture 
containing 0.3 M mannitol, 10 mM KCl, 5 mM 
potassium phosphate, 0.2 mM EDTA, 10 mM Tris-HCl 
(pH 7.4) and 0.67 (control) or 0.83 (CV-2619) mg 
mitochondrial protein, in a final volume of 1.7 ml. 
When indicated, 4 mM of glutamate or succinate and 
250 FM ADP were added. Other experimental details are 
described in section 2. 
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Table 1 
Effects of CV-2619 and calcium hopantenate administration on the respiratory and phosphorylating activities of rat 
brain mitochondria 
Dose 
(mg/kg) 
n State 3 State 4 RCI ADP/O 
(nmol 02/min per mg protein) 
Glutamate 
Control 0 8 35.7 f 1.7 8.72 I% 0.42 4.11 * 0.33 2.46 + 0.10 
CV-2619 100 6 39.4 * 2.2b 8.39 f 0.46 4.71 f 0.3gb 2.54 III 0.07 
CV-2619 300 6 38.9 f 1.4b 8.00 + 0.60” 4.87 + 0.37b 2.51 zk 0.07 
hopantenate 500 6 39.3 + l.gb 8.58 + 0.62 4.60 + 0.44” 2.48 f 0.07 
Succinate 
Control 0 10 59.5 + 4.1 29.6 f 7.0 2.19 + 0.23 1.46 f 0.09 
CV-2619 100 7 62.9 k 5.1 27.3 f 3.4 2.42 + 0.18” 1.51 * 0.04 
CV-2619 300 7 61.9 f 5.8 26.5 z!z 8.8 2.56 k 0.42a 1.53 f 0.11 
hopantenate 500 7 62.9 f 4.1 28.7 k 4.7 2.31 rt 0.25 1.48 f 0.07 
ap < 0.05, bp < 0.01 vs control 
CV-2619 or calcium hopantenate was orally administered to rats for 3 days. Brain mitochondria were isolated and the 
respiration was measured as described in section 2. Values are the mean + SD 
administered to rats for 3 days. The respiration of 
the isolated brain mitochondria was measured. 
With glutamate as substrate, CV-2619 significantly 
increased the state 3 respiration stimulated by 
ADP 0, < 0.01) and slightly decreased the state 4 
respiration after the consumption of ADP (fig.1, 
table 1). Thus, the RCI was significantly increased 
by 14-19’70 in the mitochondria from rats treated 
with CV-2619 in a dose-dependent manner (r, < 
0.01). However, CV-2619 had no effect on the 
ADP/.O ratio. With succinate as substrate, 
CV-2619 also increased the RCI in a dose- 
dependent fashion (ll-16070, p < 0.05) accom- 
panied by a slight enhancement of state 3 respira- 
tion and the suppression of state 4 respiration. On 
the other hand, calcium hopantenate had a similar 
increasing effect on the RCI, mainly by the 
enhancement of state 3 respiration in glutamate 0, 
< 0.05) but not significant in succinate oxidation. 
Thus, the effect of calcium hopantenate was less 
potent than CV-2619. The ADP/O ratio was not 
affected by the treatment of calcium hopantenate. 
Non-respiratory oxygen consumption induced 
by ascorbate and Fe’+ was also measured. Both 
CV-2619 and calcium hopantenate significantly 
decreased the activities of the oxygen consumption 
by 8-9070 @ < 0.02, table 2). 
50 
Table 2 
Effects of CV-2619 and calcium hopantenate 
administration on the non-respiratory oxygen 
consumption induced by ascorbate and Fe2+ in rat brain 
mitochondria 
Dose n Oxygen consumption 
(mg/kg) (nmol O/min 
per mg protein) 
Control 0 12 49.9 * 3.4 
CV-2619 100 8 45.2 + 4.4a 
CV-2619 300 9 45.4 + 2.6b 
Hopantenate 500 9 44.6 IL 3.1b 
a p < 0.02 and b p < 0.01 vs control 
CV-2619 or calcium hopantenate was orally 
administered to rats for 3 days. Brain mitochondria were 
isolated and oxygen consumption was measured as 
described in section 2. Values are the mean k SD 
4. DISCUSSION 
Here, we have prepared intact rat brain 
mitochondria with high respiratory and 
phosphorylating activities using the same tech- 
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nique as described by Ozawa et al. [4]. These 
values are in the same range as those reported by 
others [lo]. By using this preparation, we have 
studied ex vivo effects of CV-2619 on mitochon- 
drial functions such as the respiratory activity 
coupled with energy metabolism and the non- 
respiratory oxygen consumption. 
It has been reported that CV-2619 improves or 
protects various abnormalities, such as cerebral 
vascular lesions and cell damage, caused by 
cerebral ischemia or hypoxia [l-3]. CV-2619 also 
has been demonstrated to be effective in improving 
cerebral metabolism by suppressing the decrease of 
ATP formation in the rat ischemic brain [3]. In the 
present study, CV-2619 showed the increasing ef- 
fect of the RCI accompanied by stimulation of the 
state 3 respiration and the suppression of state 4 
respiration, but the compound did not affect the 
ADP/O ratio. These results indicate that the brain 
mitochondria from the CV-2619-treated rat can ef- 
ficiently perform ATP formation by the rigid 
coupling of electron and energy transfer. 
CV-2619 reduced the non-respiratory oxygen 
consumption induced by ascorbate and Fe’+ in rat 
brain mitochondria. It has been reported that 
ascorbate and ferrous ion nonenzymatically in- 
duced the oxygen consumption, which closely 
associated with lipid peroxidation and swelling in 
mitochondria or microsomes [6-81. In our ex- 
periments, the oxygen consumption induced by on- 
ly ferrous ion was transient (not shown) but was 
continued by the following addition of ascorbate. 
Furthermore, in accordance with data reported by 
other investigators [6,7], the oxygen consumption 
was not inhibited by preincubating with electron 
transfer inhibitors such as rotenone, antimycin A 
and KCN (not shown). Therefore, the oxygen up- 
take induced by ascorbate and Fe*+ in rat brain 
mitochondria does not occur through the 
respiratory chain. These facts indicate that brain 
mitochondria from CV-2619-treated rats can save 
oxygen consumed by the non-respiratory system. 
This effect seems to be important to protect cell 
damage of the ischemic brain, because the supply 
of oxygen is limited in ischemic anoxia. Thus, the 
well-coupling of electron and energy transfer and 
the oxygen saving action by CV-2619 treatment 
may both contribute to protection of cerebral 
damage, possibly cell membranes, against ischemic 
anoxia through the increased production of ATP. 
Although the mechanism of ex vivo action of 
CV-2619 remains unclear, studies on the direct ac- 
tion of CV-2619 on rat brain mitochondria are 
needed. Recently, Suno and Nagaoka [ 11,131 have 
reported that CV-2619 and its metabolites directly 
inhibited the lipid peroxidation by measuring the 
formation of malonedialdehyde (MDA) in rat 
brain homogenate [1 l] and mitochondria [ 131. As 
it is well known that the radicals and lipid perox- 
ides impair the mitochondrial function and con- 
struction [9, lo], the inhibitory action of MDA for- 
mation by CV-2619 may contribute to the effects 
observed in this study. 
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